Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
Public ClinicalTrials.gov record NCT00772603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Study identification
- NCT ID
- NCT00772603
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Enrollment
- 366 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- 2400mg SPN-804 Drug
- 1200mg SPN-804 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2008
- Primary completion
- Mar 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- Feb 10, 2014
2008 – 2010
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Northport | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | West Los Angeles | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Missoula | Montana | — | — |
| Not listed | Camden | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Baytown | Texas | — | — |
| Not listed | Temple | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00772603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00772603 live on ClinicalTrials.gov.